SIDE EFFECTS OF VARIOUS SCHEMES OF INTERFERON THERAPY OF CHRONIC HEPATITIS C AND THEIR CORRECTION
https://doi.org/10.21518/2079-701X-2017-15-89-91
Abstract
The aim of this work was to assess the frequency and severity of major interferon-induced side effects depending on the applied interferon drug. The study included 29 patients with chronic hepatitis C with genotype 1b, 2, 3a/b. Patients received one of three drugs: interferon-alfa-2b, peginterferon-alfa-2b or repagination-alfa-2b in combination with ribavirin. The most commonly registered side effects induced by the interferon: flu-like syndrome, leukopenia, weight loss, thrombocytopenia and depression. Flu-like symptoms and depression were more often recorded when using peginterferon-alfa-2b. The weight loss and leukopenia were often associated with the use of repagination-alpha-2b. Thrombocytopenia with approximately the same frequency was recorded when using repagination-alfa-2b and peginterferon-alfa-2b; interferon alfa-2b caused thrombocytopenia less frequently. All these side effects in one way or another were subjected to correction (recommendations for lifestyle to reduce the doses of interferons, indication of additional drugs). Thus, the applied drugs have a similar safety profile slightly differing frequency and severity of most common side effects.
About the Authors
A. M. Ryumin
Nizhny Novgorod State Medical Academy of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
O. L. Sobolevskaya
Nizhny Novgorod State Medical Academy of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
O. V. Korochkina
Nizhny Novgorod State Medical Academy of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD
References
1. Мукомолов С.Л., Левакова И.А., Синайская Е.В. Вирусные гепатиты в Российской Федерации. Проблемы и решения. Здоровье – основа человеческого потенциала: проблемы и пути их решения, 2012, 2(7): 789-791.
2. Трифонова Г.Ф., Левакова И.А., Болсун Д.Д., Мукомолов С.Л. Острый и хронический гепатит С в Российской Федерации в 1994-2013 гг. Инфекция и иммунитет, 2014, 3(4): 267-274.
3. Лиознов Д.А., Николаенко С.Л., Горчакова О.В., Дьячков А.Г. Качество жизни лиц молодого возраста, больных хроническим гепатитом С. Журнал инфектологии, 2012, 2(4): 56-59.
4. Пименов Н.Н., Чуланов В.П., Комарова С.В. Гепатит С в России: эпидемиологическая характеристика и пути совершенствования диагностики и надзора. Эпидемиология и инфекционные болезни, 2012, 3: 4-10.
5. Бакулин И.Г. Актуальные вопросы противовирусной терапии хронического гепатита В и С. Экспериментальная и клиническая гастроэнтерология, 2010, 5: 3-9.
6. Lok Sharma. Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet? Gastroenterology, 2011, 141: 1963–1967.
7. Хунафина Д.Х., Кутуев О.И., Орехова Н.А. Опыт применения α2а-пегилированного интерферона («пегасис») в этиотропной терапии больных хроническим гепатитом С. Дальневосточный Журнал Инфекционной Патологии, 2008, 12: 201-202.
8. Бакулин И.Г., Шарабанов А.С. Клиническое значение лейко- и нейтропении у пациентов хроническим гепатитом с при проведении различных режимов противовирусной терапии. Экспериментальная и клиническая гастроэнтерология, 2010, 5: 27-32.
Review
For citations:
Ryumin AM, Sobolevskaya OL, Korochkina OV. SIDE EFFECTS OF VARIOUS SCHEMES OF INTERFERON THERAPY OF CHRONIC HEPATITIS C AND THEIR CORRECTION. Meditsinskiy sovet = Medical Council. 2017;(15):89-91. (In Russ.) https://doi.org/10.21518/2079-701X-2017-15-89-91
Views:
5518
Email this article 